분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2014-12-12 11:30:57 , Hit : 1223
 FDA approves 9-valent HPV vaccine for certain cancers

FDA approvals
  
December 10, 2014
  

The FDA today approved a new vaccine for the prevention of certain diseases caused by HPV that has the potential to prevent approximately 90% of anal, cervical, vaginal and vulvar cancers.

  

See Also
HPV vaccination rates among girls lowest in states with ...
Few physicians routinely recommend HPV vaccine to boys ...
Effective implementation of nine-valent HPV vaccination could ...
  

The recombinant HPV 9-valent vaccine (Gardasil 9, Merck) covers nine HPV types, which is five more than the quadrivalent HPV vaccine (Gardasil).

The vaccine is indicated for females aged 9 to 26 years and males aged 9 to 15 years, and for cancers caused by HPV types 16, 18, 31, 33, 45, 52 and 58 and for the prevention of genital warts caused by HPV types 6 or 11.

The additional five types of HPV that Gardasil 9 adds protection against (31, 33, 45, 52 and 58) are the cause of approximately 20% of cervical cancers and are not covered in previous FDA-approved HPV vaccines.

“Vaccination is a critical public health measure for lowering the risk of most cervical, genital and anal cancers caused by HPV,” Karen Midthun, MD, director of the FDA’s Center for Biologics Evaluation and Research, said in a press release. “The approval of Gardasil 9 provides broader protection against HPV-related cancers.”

Karen Midthun, MD
Karen Midthun

A randomized controlled international study was conducted using a cohort of approximately 14,000 females (median age, 21 years) who tested negative for vaccine HPV types at the start of the study. Patients were randomly assigned Gardasil 9 or Gardasil.

Gardasil 9 was found to be 97% effective in preventing cervical, vulvar and vaginal cancers caused by the additional HPV types.

In addition, Gardasil 9 was equally as effective as Gardasil in the prevention in the four other HPV types (6, 11, 16 and 18).

There is a low incidence of anal cancer caused by the five additional HPV types. As such, the preventive analysis is based on Gardasil’s demonstrated effectiveness of 78% and additional data on antibodies in males and females who received Gardasil 9.

For children aged 9 to 15 years, the effectiveness of Gardasil 9 was identified in studies that measured antibody response to the vaccine. The study group consisted of approximately 1,200 males and 2,800 females. Their response was similar to participants aged 16 to 26 years. Therefore, the vaccine is expected to have similar effectiveness in the younger age group.

Gardasil 9 is administered as three separate vaccinations, with the initial dose followed by additional vaccinations 2 to 6 months later.

Indications are that patients vaccinated before becoming infected with the HPV strains would benefit the most from Gardasil 9.

The safety of the agent was evaluated in approximately 13,000 males and females, and the most common adverse effects were pain at the injection site, swelling, redness and headaches.







1087   옥스포드 나노포어, 휴대용 시퀀서 미니온 출시 임박  이성욱 2015/05/08 1190
1086   “Kissing Disease” Virus Promotes Malignant Breast Cancer Development  이성욱 2016/08/03 1190
1085   융합연구리뷰 | Convergence Research Review  이성욱 2016/01/08 1193
1084   생명과학 연구에서 암컷쥐가 필요한 이유  이성욱 2015/07/23 1194
1083   인류의 역사를 고스란히 보여주는 결핵균의 게놈  이성욱 2015/01/21 1201
1082   [바이오토픽] 브로드 연구소, 열띤 CRISPR 특허전쟁에서 승리  이성욱 2017/02/16 1206
1081   유전자치료제 연구개발 및 규제 동향 2015-식품의약품안전처  이성욱 2016/01/20 1210
1080   의문이 제기된 `젊은 피`의 항노화 효과  이성욱 2015/05/22 1216
1079   Cost to Develop a Drug More Than Doubles to $2.56 Billion  이성욱 2014/11/21 1219
  FDA approves 9-valent HPV vaccine for certain cancers  이성욱 2014/12/12 1223
1077   Gilead wins European approval of next-generation hepatitis C drug  이성욱 2014/11/20 1225
1076   정밀의학의 끝: 개인화된 종양백신을 개발하는 과학자들  이성욱 2016/04/26 1225
1075   특허전쟁: 미국 특허청, CRISPR의 특허권 중재 시작  이성욱 2016/03/08 1226
1074   미국 과학·공학·의학 아카데미, 「GM 베이비」의 진행방향에 대한 윤곽 발표  이성욱 2017/02/16 1228
1073   세계 20여 개국 과학자들, 유전자편집 정상회담 개최  이성욱 2015/12/05 1231
1072   CRISPR의 능력을 배가(倍加)시키는 미니 유전자  이성욱 2015/04/02 1233
1071   Janssen, Isis Pharma Ink Up-to-$835M Antisense Agreement  이성욱 2015/01/07 1237
1070   줄기세포로 만든 초기 난자와 정자  이성욱 2014/12/31 1239
1069   맹인을 위한 유전자치료의 쇠퇴  이성욱 2015/05/08 1246
1068   유전자편집치료에 희망을 준 백혈병치료  이성욱 2015/11/11 1246

[1][2][3][4][5][6][7][8][9] 10 ..[64] [다음 10개]
 

Copyright 1999-2024 Zeroboard / skin by ROBIN